Dr. Brian J. Bearie
Emergency Medicine (Emergency Medicine Physician)
2101 N Waterman Ave
San Bernardino, CA 92404
Who else practices at this address →
San Bernardino County includes primary care (5% of residents) and mental health (26% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Years since graduation
- 27
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 854
Licensed in California since 2000, according to the Medical Board of California. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Emergency Medicine Physician primary
CA license A73011 (first issued 2000; current)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- St Bernardine Medical Center San Bernardino, CA
Medical groups
- Southern California Emergency Medicine (45 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 854
- Services billed
- 2,140
- Patients’ average age
- 68
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 20-29 minutes | 591 | 485 |
| Injection, dexamethasone sodium phosphate, 1 mg | 585 | 60 |
| Established patient office or other outpatient visit, 30-39 minutes | 392 | 316 |
| New patient office or other outpatient visit, 30-44 minutes | 302 | 302 |
| Injection of drug or substance under skin or into muscle | 182 | 136 |
| Injection, ketorolac tromethamine, per 15 mg | 178 | 74 |
| New patient office or other outpatient visit, 45-59 minutes | 166 | 166 |
| Urinalysis, manual test | 125 | 119 |
| Injection, ceftriaxone sodium, per 250 mg | 92 | 25 |
| X-ray of chest, 2 views | 61 | 60 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Tramadol Hcl Other prescribers in San Bernardino, CA | 19 |
| Santyl (collagenase clostridium hist.) | 11 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Industry-funded research
Named as a principal investigator on 11 industry-funded studies in 2025, from 5 companies. The companies reported $723,064 in research payments for these studies, mostly to the institutions running them.
- A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ≥18 Years of Age for the Prevention of Acute Gastroenteritis
ModernaTX, Inc. · Active, not recruiting · NCT06592794 - A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ≥50 Years of Age
ModernaTX, Inc. · Completed · NCT06602024 - A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults
ModernaTX, Inc. · Active, not recruiting · NCT05164094 - A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ≥12 Years of Age to Prevent COVID-19
ModernaTX, Inc. · Completed · NCT05815498 - A Phase I-III Randomized Double blind Study to Evaluate the Safety and Neutralizing Activity of AZD5156-AZD3152 for Pre exposure Prophylaxis of COVID 19 in Participants with Conditions Causing Immune Impairment
AstraZeneca UK Limited - Clinical Evaluation of the Sekisui OSOM COVID-19 Test
Sekisui Diagnostics LLC - Performance Evaluation of the OSOM COVID-19 Flu A&B Combo Test
Sekisui Diagnostics LLC - CLP 0019 FebriDx Method Comparison Study Protocol
Lumos Diagnostics, Inc. - A phase 3,global,randomized,modified double blind,placebo controlled,study to evaluate the efficacy,immunogenicity,and safety of IVX A12,a respiratory syncytial virus RSV and human metapneumovirus hMPV virus like part…
AstraZeneca Pharmaceuticals LP - A Study of mRNA-based Influenza and SARS-CoV-2 (COVID-19) Multi-component Vaccines in Healthy Adults
ModernaTX, Inc. · Completed · NCT05827926
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.